关于全资子公司获得药品注册证书的公告 证券代码：301075 证券简称：多瑞医药 公告编号：2023-066 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司 西藏多瑞医药股份有限公司（以下简称"公司"）全资子公司湖北 多瑞药业有限公司近日收到国家药品监督管理局核准签发的关于盐 酸文拉法辛缓释胶囊的《药品注册证书》，现将有关信息公告如下： | 一、药品基本情况 | | --- | | 药品名称 | 盐酸文拉法辛缓释胶囊 | | | | | --- | --- | --- | --- | --- | | 主要成分 | 盐酸文拉法辛 | | | | | 剂型 | 胶囊剂 | | | | | 规格 | 150mg、75mg | | | | | 证书编号 | 2023S01258、2023S01259 | | | | | 药品批准文号 | 国药准字 H20234024、国药准字 H20234025 | | | | | 药品批准文号有 | 至 2028 08 07 | 年 | 月 | 日 | | 效期 | | | | | | 申请事项 | 药品注 ...

西藏多瑞医药股份有限公司 投资者关系活动记录表 编号：2023-050 投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他 参与单位及人员 通过中国证券网以网上业绩说明会的形式与广大投资者交流 时间 2023年05月15日 15:30-16:30 地点 中国证券网（http://roadshow.cnstock.com） 上市公司接待人员 董事长、总经理 邓勇先生； 副总经理、董事会秘书 敖博先生； 财务总监 李超先生； 副总经理 韦文钢先生； 销售总监 张金先生； 独立董事 刘颖斐女士； 保荐代表人 马晓露先生。 投资者关系活动主要 内容介绍 公司于2023年04月25日发布了《2022年年度报告》，为便于广大投资者 进一步了解公司经营状况及未来发展，公司于2023年05月15日15:30-16:30在 中国证券网举行2022年年度报告网上业绩说明会。本次业绩说明会采用网络 远程的方式与投资者互动交流，主要沟通内容如下： 1、公司上市以来连续业绩下滑，请问公司在研发喝产品储备方面有什么 计划吗？未来有什么业绩增长的看点？ ...

Financial Performance - The company's revenue for Q1 2023 was ¥78,085,173.39, representing a 7.13% increase compared to ¥72,887,112.31 in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥2,417,228.83, a decrease of 127.12% from a profit of ¥8,912,462.89 in the previous year[5]. - The company's basic earnings per share were -¥0.03, down 127.27% from ¥0.11 in the same period last year[5]. - Operating profit turned negative at -¥2,364,058.33, compared to a profit of ¥9,381,414.07 in the previous period[21]. - Net profit for the current period was -¥2,520,711.19, a significant decline from ¥8,524,544.62 in the previous period[21]. - The company achieved a total comprehensive income of ¥5,380,673.81, down from ¥8,524,544.62 in the previous period[22]. Cash Flow - The cash flow from operating activities improved significantly to ¥17,673,168.97, compared to a negative cash flow of ¥15,632,963.13 in the same period last year, marking a 213.05% increase[5]. - The company reported a net cash flow from operating activities of ¥17,673,168.97, recovering from a negative cash flow of -¥15,632,963.13 in the previous period[25]. - Cash and cash equivalents increased to CNY 500,489,923.64 from CNY 425,764,874.23, representing a growth of approximately 17.5%[16]. - Cash and cash equivalents at the end of the period increased to ¥500,489,923.64, compared to ¥433,237,666.85 at the end of the previous period[26]. - The company generated cash inflows from investment activities totaling ¥166,574,437.19, with net cash flow from investment activities of ¥9,231,859.19[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥932,156,719.79, reflecting a 3.70% increase from ¥898,868,684.29 at the end of the previous year[5]. - The company's current assets reached CNY 675,995,466.59, up from CNY 647,426,048.56, indicating an increase of about 4.0%[17]. - The total liabilities of the company as of March 31, 2023, were CNY 173,361,491.14, compared to CNY 145,454,129.45 at the beginning of the year, showing an increase of around 19.2%[18]. - The company's equity attributable to shareholders reached CNY 757,009,963.12, up from CNY 751,525,806.95, reflecting a growth of about 0.5%[18]. - Total non-current assets amounted to CNY 256,161,253.20, slightly up from CNY 251,442,635.73, reflecting an increase of about 1.4%[17]. Expenses - Research and development expenses increased by 46.72% to ¥6,839,149.50, up from ¥4,661,255.97 in the previous year, indicating a focus on innovation[10]. - Total operating costs increased to ¥81,960,671.26, up from ¥73,053,209.52, reflecting a rise of 12.1%[20]. - The company reported a significant increase in operating costs, which rose by 185.80% to ¥27,537,913.38, compared to ¥9,635,450.17 in the previous year[10]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,963[12]. - The first quarter report of Xizang Duorui Pharmaceutical Co., Ltd. is unaudited[27].

Financial Performance - In 2022, the company's operating revenue was CNY 401.05 million, a decrease of 24.28% compared to the previous year[3]. - The net profit attributable to the parent company was CNY 20.50 million, down 70.07% year-on-year[3]. - The cash flow from operating activities for 2022 was ¥1,126,629.23, a significant decline of 97.66% from ¥48,149,282.18 in 2021[27]. - The basic earnings per share for 2022 was ¥0.26, a decrease of 75.24% compared to ¥1.05 in 2021[27]. - The weighted average return on equity for 2022 was 2.69%, down from 17.25% in 2021[27]. - The gross profit margin for the pharmaceutical manufacturing sector was 76.98%, down 11.63% from the previous year[57]. - The sales volume of pharmaceutical products decreased by 29.86%, leading to a corresponding drop in production volume by 35.80%[59]. - The company reported a significant increase in investment cash inflow by 325.11% to ¥425,881,915.71, while investment cash outflow rose by 191.96% to ¥628,725,447.82[72]. - The company reported a total revenue of 1.5 billion CNY for the year 2022, representing a year-on-year increase of 20%[120]. Market and Product Development - The company has obtained 46 patents, including 12 invention patents, and is actively developing new products such as Compound Sodium Acetate Ringer's Injection and Levofloxacin Sodium Chloride Injection, which are in the registration phase[42]. - The company aims to strengthen its position in the plasma substitute and crystal liquid market with new product launches[69]. - The company plans to accelerate the research and development of chemical raw materials and formulations, utilizing capital markets for pilot scale-up and process validation[101]. - The company is focusing on expanding its market presence and enhancing its product offerings through new product development and technology advancements[124]. - The company is actively pursuing strategic acquisitions to bolster its market position and enhance its operational capabilities[126]. - The company plans to enhance its digital marketing strategy, aiming for a 25% increase in online sales channels[120]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million CNY allocated for this purpose[120]. Operational Risks and Challenges - The decline in performance was primarily due to the expiration of local medical insurance adjustments, economic downturn, and product price reductions[3]. - The company is facing potential risks from the gradual removal of local medical insurance listings, which could adversely affect sales if new products do not launch in time[38]. - The company’s reliance on Sodium Acetate Ringer's Injection poses a risk to its financial stability if it cannot maintain market leadership or if new product development is delayed[48]. - The company is facing risks from price reductions due to increasing competition and government policies aimed at controlling drug prices[103]. - The company has identified 8,766 million yuan in raised funds for various projects, with 2,630 million yuan allocated for permanent working capital[92]. Corporate Governance and Compliance - The company held 10 board meetings during the reporting period, complying with legal regulations and company bylaws[112]. - The company maintained a high level of information disclosure, ensuring timely and accurate communication with investors[113]. - The company has independent operations in business, personnel, assets, institutions, and finance, ensuring no interference from controlling shareholders[115]. - The company emphasized the importance of compliance with legal and regulatory requirements in its operations[147]. - The company’s board of directors actively considered the interests of minority shareholders in decision-making processes[146]. Research and Development - Research and development (R&D) expenses accounted for 6.60% of total revenue, showing a steady increase[51]. - The company’s R&D investment in 2022 amounted to ¥26,452,560.84, representing 6.60% of total operating revenue, an increase from 4.54% in 2021[70]. - The company is investing 200 million CNY in R&D for new technologies and product development in the upcoming year[120]. - The company is committed to sustainability and has initiated projects aimed at reducing its carbon footprint by 25% by 2025[131]. Employee and Compensation Policies - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 5.5449 million[141]. - The company emphasizes performance and responsibilities in determining remuneration levels[139]. - The company aims to enhance employee training and development, focusing on vocational skills and high-level talent cultivation in 2023[154]. - The company has a total of 318 employees who received compensation during the reporting period[151]. Future Outlook - The company has set a revenue guidance of 1.8 billion CNY for 2023, indicating a growth target of 20%[120]. - New product launches are expected to contribute an additional 300 million CNY in revenue in 2023[120]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[188]. - The company is set to launch two new products in Q2 2023, expected to contribute an additional 200 million CNY in revenue[188].

证券代码：301075 证券简称：多瑞医药 公告编号：2023-044 西藏多瑞医药股份有限公司 2023 年 4 月 25 日 出席本次年度业绩说明会的人员有：董事长、总经理邓勇先生， 副总经理、董事会秘书敖博先生，财务总监李超先生，副总经理韦文 钢先生，销售总监张金先生，独立董事刘颖斐女士，保荐代表人马晓 露先生。 欢迎广大投资者积极参与！ 特此公告。 西藏多瑞医药股份有限公司 董事会 关于举办 2022 年度网上业绩说明会的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 西藏多瑞医药股份有限公司（以下简称"公司"）2022 年年度报 告全文及摘要已于 2023 年 4 月 25 日刊登于中国证监会指定信息披露 网站巨潮资讯网（www.cninfo.com.cn）。为便于投资者能够进一步了 解公司的生产经营情况，公司将于 2023 年 5 月 15 日（星期一） 15:30-16:30 在中国证券网举办 2022 年度网上业绩说明会。本次网 上业绩说明会将采用网络远程的方式举行，投资者可登录中国证券网 （https:/ ...

Financial Performance - Revenue for Q3 2022 was CNY 117,449,975.50, a decrease of 22.98% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 8,655,549.55, down 29.23% year-on-year[5] - Basic earnings per share decreased by 45.00% to CNY 0.11[5] - Total operating revenue for the third quarter of 2022 was RMB 302,488,326.43, a decrease of 23.7% compared to RMB 396,422,129.81 in the same period last year[20] - The net profit for Q3 2022 was CNY 21,603,579.65, a decrease of 54.4% compared to CNY 47,286,377.81 in Q3 2021[22] - Operating profit for Q3 2022 was CNY 25,513,696.96, down 52.2% from CNY 53,415,641.67 in the same period last year[22] - Total revenue from operating activities was CNY 368,629,443.63, a decline of 18.4% compared to CNY 451,532,964.63 in Q3 2021[26] - The total comprehensive income for Q3 2022 was CNY 21,603,579.65, significantly lower than CNY 47,286,377.81 in Q3 2021[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 887,414,836.06, an increase of 4.23% from the end of the previous year[5] - The total assets of the company as of September 30, 2022, were RMB 887,414,836.06, compared to RMB 851,423,622.82 at the beginning of the year, an increase of 4.2%[20] - The total liabilities increased to RMB 130,174,324.76 from RMB 62,789,771.85, indicating a significant rise of 107.0%[19] Cash Flow and Investments - The company's cash and cash equivalents decreased to RMB 534,621,907.83 from RMB 610,930,333.64 at the beginning of the year, a decline of 12.4%[17] - The cash flow from operating activities showed a net outflow of CNY 27,158,694.67, contrasting with a net inflow of CNY 39,546,864.33 in the previous year[26] - Investment activities resulted in a net cash outflow of CNY 156,733,060.83, compared to a smaller outflow of CNY 3,993,603.56 in Q3 2021[27] - The cash and cash equivalents at the end of Q3 2022 stood at CNY 311,890,955.77, down from CNY 637,379,375.20 at the end of Q3 2021[27] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,012[11] - The largest shareholder, Tibet Jiakang Times Technology Development Co., Ltd., holds 58.35% of the shares[11] Operational Metrics - Operating costs rose by 60.35% due to changes in product structure[9] - Total operating costs amounted to RMB 288,836,450.34, down from RMB 346,559,133.52, reflecting a reduction of 16.7% year-over-year[20] - Research and development expenses were RMB 13,101,570.92, down from RMB 17,360,705.80, a decrease of 24.9% year-over-year[20] - The company reported a significant increase in accounts receivable financing by 159.41% due to the receipt of bank acceptance bills[9] - Accounts receivable decreased to RMB 87,790,835.03 from RMB 98,290,746.40, representing a reduction of 10.2%[17] - Inventory increased by 40.70%, primarily due to an increase in stock[9] - Inventory increased to RMB 13,822,877.74 from RMB 9,824,013.58, marking a rise of 40.1%[17] Other Income and Expenses - Other income increased by 152.51% as a result of higher government subsidies received[9] - The company reported a decrease in other income to CNY 11,683,038.23 from CNY 4,626,692.22 in the previous year[22] - The company experienced a credit impairment loss of CNY -2,798,232.37, worsening from CNY -1,061,861.24 in Q3 2021[22] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.28, a decrease from CNY 0.82 in the same quarter last year[23]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥185,038,350.93, a decrease of 24.14% compared to ¥243,934,796.22 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was ¥13,832,403.60, down 62.69% from ¥37,072,692.67 in the previous year[24]. - The net profit after deducting non-recurring gains and losses was ¥3,903,030.73, a decline of 88.18% compared to ¥33,008,014.49 in the same period last year[24]. - The net cash flow from operating activities was ¥3,873,637.20, a significant drop of 91.85% from ¥47,540,429.26 in the previous year[24]. - Basic and diluted earnings per share were both ¥0.17, down 72.58% from ¥0.62 in the same period last year[24]. - The weighted average return on net assets was 1.69%, a decrease of 12.52% compared to 14.21% in the previous year[24]. - The company's net profit attributable to shareholders decreased by 62.69% to CNY 13,832,403.60, primarily due to a reduction in revenue and an increase in expenses[44]. - The total profit for the first half of 2022 was ¥15,388,341.81, down 62.0% from ¥40,439,930.78 in the first half of 2021[128]. Revenue Sources - The company's main product, Sodium Acetate Ringer's Injection, generated sales revenue of CNY 142.19 million, accounting for 76.84% of total revenue during the reporting period[33]. - The sales revenue from Cefotaxime Sodium Injection and other products was CNY 42.85 million, representing 23.16% of total revenue[33]. - The company's sales revenue for the core product, Sodium Acetate Ringer's Injection, was CNY 142,190,268.06, representing a decrease of 34.68% compared to the previous year[46]. - The sales revenue of the core product, Sodium Acetate Ringer's Injection, reached RMB 142,190,300, accounting for 76.84% of the company's main business income[66]. Market Position and Strategy - The market share of Sodium Acetate Ringer's Injection in China is close to 90%, making it the leading product in its category[35]. - The company has established a marketing network covering 29 provinces and municipalities, with sales in over 800 hospitals, including more than 500 tertiary hospitals[33]. - The company is focusing on expanding its product line in niche areas such as plasma substitutes and pediatric medications, enhancing its competitive edge[40]. - The company plans to accelerate new product development in areas such as plasma substitutes, emergency medications, pediatric medications, and psychiatric medications to cultivate new profit growth points[66]. - The company is actively developing new products in niche areas such as plasma substitutes and pediatric medications, but faces risks related to the lengthy and uncertain drug registration process[68]. Research and Development - The company has obtained a total of 50 patents, including 12 invention patents, 36 utility model patents, and 2 design patents, with 10 invention patents currently under application[33]. - R&D expenses accounted for 5.01% of the company's operating revenue during the reporting period, reflecting the company's commitment to innovation[41]. - The company aims to enhance its research and development capabilities to innovate and improve product offerings[143]. Financial Position - Total assets at the end of the reporting period were ¥872,409,341.19, an increase of 2.46% from ¥851,423,622.82 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were ¥750,296,760.44, down 5.38% from ¥792,918,557.15 at the end of the previous year[24]. - Cash and cash equivalents at the end of the reporting period amounted to ¥586,398,232.02, representing 67.22% of total assets, a decrease of 4.53% compared to the previous year[49]. - Accounts receivable decreased to ¥84,075,620.92, accounting for 9.64% of total assets, down by 1.90% year-on-year[49]. - Inventory increased significantly to ¥18,157,559.66, now representing 2.08% of total assets, an increase of 0.93% compared to the previous year[49]. Investment and Financing - The total amount of raised funds was ¥54,540.00 million, with ¥8,276.56 million invested during the reporting period[54]. - The company has committed to various investment projects, with a total commitment of ¥39,438 million, of which ¥8,276.56 million has been invested in the reporting period[57]. - The company has ongoing new product development projects, with a total investment of ¥7,359 million, and a progress rate of 0% reported for the current period[57]. - The company raised CNY 3,600,000.00 from minority shareholders and CNY 40,000,000.00 from loans during the financing activities[136]. Risks and Challenges - The company faces risks of price declines for core products due to increasing pressure from national medical insurance policies and competition in the pharmaceutical market[67]. - The core product sodium acetate Ringer's injection has not been included in the national volume-based procurement list, which poses risks if it is included in local procurement lists without winning bids[68]. - The company plans to expand its self-pay market and accelerate the development of new products to mitigate the impact of being removed from local medical insurance directories[68]. Corporate Governance and Compliance - The half-year financial report was not audited[84]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[60][61]. - There were no significant related party transactions during the reporting period[87]. - The company has maintained a commitment to social responsibility while pursuing sustainable development[79]. Shareholder Information - The total number of shares is 80,000,000, with 75% being restricted shares[106]. - The largest shareholder, Tibet Jiakang Times Technology Development Co., Ltd., holds 58.35% of the shares, totaling 46,677,966 shares[107]. - The second-largest shareholder, Jiaxing Qiuying Equity Investment Partnership, holds 8.01% of the shares, totaling 6,406,780 shares[107]. Accounting Policies - The company adheres to the enterprise accounting standards, ensuring that its financial statements accurately reflect its financial position and operating results[156]. - The company utilizes the Chinese Yuan (RMB) as its functional currency for accounting purposes[159]. - The company has established specific accounting policies for financial instruments, fixed asset depreciation, and revenue recognition based on its operational characteristics[165].

Financial Performance - The company's operating revenue for 2021 was ¥529,615,447.55, representing an increase of 8.05% compared to ¥490,164,744.19 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥68,507,883.04, a decrease of 25.53% from ¥91,988,592.72 in 2020[18]. - The net cash flow from operating activities was ¥48,149,282.18, down 24.34% from ¥63,639,874.30 in the previous year[18]. - Basic earnings per share for 2021 were ¥1.05, a decline of 31.37% compared to ¥1.53 in 2020[18]. - Total assets at the end of 2021 reached ¥851,423,622.82, an increase of 129.49% from ¥371,006,145.17 at the end of 2020[18]. - The net assets attributable to shareholders increased by 227.16% to ¥792,918,557.15 from ¥242,361,001.66 in 2020[18]. - The company reported a weighted average return on equity of 17.25%, down from 46.85% in the previous year[18]. - The fourth quarter revenue was ¥133,193,317.74, with a net profit of ¥19,163,573.63 attributable to shareholders[20]. - The company's non-recurring gains totaled CNY 10,287,621.32 in 2021, a decrease of 69.7% from CNY 33,854,842.62 in 2020[24]. - The government subsidies recognized in the current period amounted to CNY 10,971,571.88, down from CNY 34,384,862.30 in 2020[23]. Market and Product Overview - The domestic healthcare expenditure has grown from approximately CNY 2 trillion in 2010 to CNY 7.23 trillion in 2020, with a compound annual growth rate (CAGR) of 13.71%[27]. - The market size for blood plasma substitutes in China was approximately CNY 55.368 billion in 2020, with a CAGR of about 5.99% from 2013 to 2020[28]. - The market for therapeutic crystalloid products in China grew from CNY 0.672 billion in 2013 to CNY 2.363 billion in 2020, achieving a CAGR of 19.68%[29]. - The company's main product, sodium acetate Ringer's injection, holds a market share of nearly 90% in the first half of 2021[32]. - The core product, Sodium Acetate Ringer's Injection, generated sales revenue of ¥465,358,327.89, accounting for 87.87% of total revenue during the reporting period[34][37][43]. - The company achieved sales revenue of ¥64,257,119.66 from Cefotaxime Sodium Injection, representing 12.13% of total revenue[34][37]. Research and Development - The company has obtained 48 patents, including 10 invention patents, 36 utility model patents, and 2 design patents, with 8 invention patents currently under application[34][42]. - The company has 64 R&D personnel, accounting for 21.40% of total employees, indicating a strong focus on research and development[44]. - The company emphasizes innovation in R&D, focusing on plasma substitutes and emergency medications, with over 20 products in the research pipeline[43][42]. - The company is advancing multiple R&D projects, including sodium bicarbonate injection and venlafaxine sustained-release capsules, aimed at expanding its product line and market presence[62]. Financial Management and Governance - The company has established a sound financial and accounting management system, with independent accounting professionals managing financial records and making financial decisions[97]. - The company has not faced any disciplinary actions from the China Securities Regulatory Commission or the Shenzhen Stock Exchange regarding internal control issues in 2021[95]. - The company has a complete procurement, production, and sales system, with independent operational sites and decision-making capabilities[96]. - The company has held multiple shareholder meetings in 2021, with attendance rates of 100% and 73.73% for different meetings[99]. - The company has established a remuneration decision-making process based on national laws and regulations, as well as company performance[109]. Employee and Social Responsibility - The company aims to enhance employee training and development, focusing on vocational skills and high-level talent cultivation in 2022[123]. - The company actively engages in corporate social responsibility, including donations to local schools in Changdu, Tibet, to support underprivileged students[146]. - The company has a strong focus on sustainable development, balancing economic and social benefits[146]. Future Outlook - The company provided a positive outlook for 2022, projecting a revenue growth of 20% to 1.8 billion RMB, driven by new product launches and market expansion strategies[153]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market penetration by the end of 2023[155]. - The company aims to invest 200 million RMB in technology upgrades over the next two years to improve production capabilities and reduce costs[152]. Risk Management - The company faces potential risks from the removal of sodium acetate Ringer's injection from local medical insurance directories, which could impact sales growth[30]. - The company is facing risks from the national volume-based procurement policy, with its core product not yet included in the national procurement list, which could adversely affect sales in key regions[87]. - The company has established a comprehensive internal control system to effectively mitigate operational risks[135].

Financial Performance - The company's revenue for Q1 2022 was ¥72,887,112.31, a decrease of 40.23% compared to ¥121,941,030.65 in the same period last year[3] - Net profit attributable to shareholders was ¥8,912,462.89, down 59.10% from ¥21,792,577.65 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥1,334,047.77, a significant decline of 92.62% from ¥18,086,835.01 in the previous year[3] - Total operating revenue for the current period was ¥72,887,112.31, a decrease of 40.2% compared to ¥121,941,030.65 in the previous period[16] - Net profit for the current period was ¥8,524,544.62, a decline of 59.3% from ¥20,988,719.93 in the previous period[18] - Operating profit decreased to ¥9,381,414.07, down 60.5% from ¥23,779,164.45[17] - Basic and diluted earnings per share were both ¥0.11, compared to ¥0.36 in the previous period[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥15,632,963.13, compared to a positive ¥21,967,398.51 in the same period last year, marking a 171.16% decrease[3] - Cash flow from operating activities showed a net outflow of ¥15,632,963.13, contrasting with a net inflow of ¥21,967,398.51 in the previous period[21] - Cash and cash equivalents at the end of the period were ¥433,237,666.85, down from ¥119,285,563.08 at the end of the previous period[21] - The company's cash and cash equivalents decreased from ¥610,930,333.64 at the beginning of the year to ¥563,769,166.85 at the end of the reporting period, a decline of approximately 7.7%[12] - Investment activities resulted in a net cash outflow of ¥31,499,953.66, compared to a smaller outflow of ¥1,864,043.94 previously[21] - Financing activities generated a net cash outflow of ¥400,000.00, compared to an outflow of ¥5,309,736.10 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥842,026,922.74, a decrease of 1.10% from ¥851,423,622.82 at the end of the previous year[3] - Total assets decreased from ¥851,423,622.82 to ¥842,026,922.74, a decline of about 1.7%[15] - Total liabilities decreased from ¥62,789,771.85 to ¥45,268,527.15, a reduction of approximately 28.1%[14] - The company's total equity increased from ¥788,633,850.97 to ¥796,758,395.59, an increase of about 1.4%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,069, with no preferred shareholders[9] - The largest shareholder, Tibet Jiakang Times Technology Development Co., Ltd., holds 58.35% of shares, totaling 46,677,966 shares, with 2,100,000 shares pledged[9] - The number of shares held by the top ten shareholders reflects a concentration of ownership, with the top shareholder alone holding over 58%[9] Operational Challenges - The company's core product, sodium acetate injection, experienced a sales decline due to local medical insurance adjustments, COVID-19 impacts, and a 10% decrease in average selling price[8] - The company reported a significant increase in credit impairment losses of 599.27%, amounting to ¥1,220,031.51, due to a reduction in bad debt provisions[8] - Other income increased by 103.99% to ¥8,327,479.77, primarily due to an increase in government subsidies received[8] Inventory and Receivables - Accounts receivable decreased from ¥98,290,746.40 to ¥69,758,683.26, representing a reduction of about 29%[12] - Inventory increased from ¥9,824,013.58 to ¥12,041,838.71, marking an increase of approximately 22.4%[13] - Accounts receivable financing rose by 81.94% to ¥3,703,173.46, attributed to an increase in received bank acceptance bills[7] Audit and Reporting - The company did not conduct an audit for the first quarter report[22] - The company has not disclosed any new product developments or market expansion strategies in the current report[11]

Financial Performance - The company's operating revenue for 2021 was ¥529,615,447.55, representing an increase of 8.05% compared to ¥490,164,744.19 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥68,507,883.04, a decrease of 25.53% from ¥91,988,592.72 in 2020[18]. - The net cash flow from operating activities was ¥48,149,282.18, down 24.34% from ¥63,639,874.30 in the previous year[18]. - Basic earnings per share for 2021 were ¥1.05, a decline of 31.37% compared to ¥1.53 in 2020[18]. - The total assets at the end of 2021 amounted to ¥851,423,622.82, an increase of 129.49% from ¥371,006,145.17 at the end of 2020[18]. - The net assets attributable to shareholders reached ¥792,918,557.15, up 227.16% from ¥242,361,001.66 in 2020[18]. - The company reported a weighted average return on equity of 17.25% for 2021, down from 46.85% in 2020[18]. - The gross profit margin for the pharmaceutical manufacturing industry was 88.61%, a decrease of 2.34% compared to the previous year[49]. - The total operating cost for the pharmaceutical manufacturing sector was CNY 60,327,111.01, reflecting a year-on-year increase of 35.91%[49]. Revenue Sources - The core product, Sodium Acetate Ringer's Injection, generated sales revenue of ¥465,358,327.89, accounting for 87.87% of total revenue during the reporting period[34][37][43]. - The company achieved sales revenue of ¥64,257,119.66 from Cefotaxime Sodium Injection, representing 12.13% of total revenue[34][37]. - The company’s core product has not yet been included in the national volume-based procurement list, which may affect its sales dynamics in key regions[31]. - The company relies heavily on Sodium Acetate Ringer's Injection for revenue, posing a risk if it cannot maintain its market position or if new product development does not meet expectations[40][42]. Market and Product Development - The company has developed a new production technology for colloidal solutions, which reduces production costs and time while ensuring high product quality[33]. - The company is advancing multiple R&D projects, including sodium bicarbonate injection and venlafaxine sustained-release capsules, aimed at enhancing its product line and market competitiveness[62]. - The company is accelerating the development of new products in the fields of plasma substitutes, emergency medications, pediatric medications, and psychiatric medications to diversify its revenue sources[86]. - The company has established a marketing network covering 29 provinces and municipalities, with its main products sold in over 800 hospitals nationwide, including more than 500 tertiary hospitals[35][41]. Research and Development - The company has 64 R&D personnel, accounting for 21.40% of total employees, indicating a strong focus on research and development[44]. - The company has obtained 48 patents, including 10 invention patents, 36 utility model patents, and 2 design patents, with 8 invention patents currently under application[34][42]. - The number of R&D personnel decreased by 4.48% to 64 from 67 in the previous year, with a slight increase in the proportion of bachelor's degree holders[63]. Cash Flow and Investments - Operating cash inflow totaled CNY 611,479,125.47, a 4.25% increase from CNY 586,564,676.94[64]. - Investment cash outflow surged by 323.71% to CNY 215,345,754.75 from CNY 50,823,985.30[64]. - Financing cash inflow increased significantly by 1,257.85% to CNY 557,803,960.00 from CNY 41,080,000.00[64]. - The net increase in cash and cash equivalents was CNY 376,278,639.03, a dramatic rise of 4,126.68% from CNY 8,902,460.58[64]. Corporate Governance - The company maintained independence from its controlling shareholders in business, personnel, assets, institutions, and finance, ensuring a complete and autonomous operational capability[96]. - The company has established a sound financial and accounting management system, with independent accounting professionals managing financial records and making financial decisions[97]. - The company has a total of 7 board members, including 3 independent directors[109]. - The company has a robust internal control system that will continue to be optimized for healthy operations[95]. Employee and Management - The total number of employees at the end of the reporting period was 299, with 107 in the parent company and 192 in major subsidiaries[121]. - The company emphasizes employee training and development, with plans to enhance vocational skills and cultivate high-level talent in 2022[123]. - The total remuneration for the chairman and general manager, Mr. Deng Yong, was CNY 741,500[110]. Dividend Policy - The company plans to conduct at least one profit distribution annually, with cash distribution preferred, contingent on meeting certain financial conditions[126]. - The company proposed a cash dividend of 6.25 CNY per 10 shares, totaling 50,000,000 CNY (including tax) for the reporting period[133]. - The total distributable profit for the year was 115,955,981.72 CNY, with the cash dividend representing 100% of the profit distribution[133]. Social Responsibility and Compliance - The company actively engages in corporate social responsibility, including donations to local schools in Changdu, Tibet, to support underprivileged students[146]. - The company emphasizes compliance with environmental laws and has established internal standards for environmental protection, with no pollution incidents reported[144]. - The company has committed to long-term stability in its shareholding structure, with no plans for share transfers during the lock-up period[149].